Sugi Predict

Sugi Predict / Compounds / SCHEMBL4476337

SCHEMBL4476337

SCHEMBL4476337

CON(C)C(=O)C(NC(=O)OC(C)(C)C)C(C)C

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 3/20 0.49
▸ CTSS P25774 2/20 0.49
▸ CA2 P00918 2/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ PREP P48147 1/20 0.43
▸ JAK3 P52333 1/20 0.42
▸ BTK Q06187 1/20 0.42
▸ TRPA1 O75762 2/20 0.42
▸ CTSL P07711 1/20 0.42
▸ CTSB P07858 1/20 0.42
▸ CYP2D6 P10635 1/20 0.41
▸ PSENEN Q9NZ42 1/20 0.39
▸ ELANE P08246 1/20 0.36
▸ KLK5 Q9Y337 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4476340 1.00 CTSK (0.49) CTSKCTSSCA2CA1CA7
SCHEMBL1655475 1.00 CTSK (0.49) CTSKCTSSCA2CA1CA7
SCHEMBL23990580 0.88 JAK3 (0.41) CTSKCTSSCA2CA1CA7
SCHEMBL1204596 0.85 CTSS (0.54) CTSKCTSSCA2CA1CA7
SCHEMBL20028616 0.85 CTSS (0.54) CTSKCTSSCA2CA1CA7
SCHEMBL12189209 0.85 CTSS (0.54) CTSKCTSSCA2CA1CA7
SCHEMBL1204594 0.85 CTSS (0.54) CTSKCTSSCA2CA1CA7
SCHEMBL14778518 0.85 CTSK (0.53) CTSKCTSSCA2CA1CA7
SCHEMBL3212854 0.85 CTSK (0.53) CTSKCTSSCA2CA1CA7
SCHEMBL3212857 0.85 CTSK (0.53) CTSKCTSSCA2CA1CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12428403-B2 N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-09-30 — — US disclosed
WO-2024259171-A9 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2025-01-23 — — WO disclosed
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2025-01-09 — — US disclosed
WO-2024259171-A2 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2024-12-19 — — WO disclosed
CN-115485273-B N- (heterocyclyl and heterocyclylalkyl) -3-benzyl pyridin-2-amine derivatives as SSTR4 agonists 武田药品工业株式会社 2024-08-13 — — CN disclosed
CN-117529476-A Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments 亚飞络思制药公司 2024-02-06 — — CN disclosed
US-20230192659-A1 N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-06-22 — — US disclosed
US-20230192659-A1 N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-06-22 — — US disclosed
EP-4126849-A1 N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS Takeda Pharmaceutical Company Limited (JP) 2023-02-08 — — EP disclosed
CN-115485273-A N- (heterocyclyl and heterocyclylalkyl) -3-benzylpyridin-2-amine derivatives as SSTR4 agonists 武田药品工业株式会社 2022-12-16 — — CN disclosed
US-7423058-B2 Inhibitors of hepatitis C virus NS3 protease SCHERING CORPORATION (US) 2008-09-09 — — US disclosed
US-20070142301-A1 Novel inhibitors of Hepatitis C virus NS3 protease MERCK SHARP & DOHME CORP. 2007-06-21 — — US disclosed
US-20070142301-A1 Novel inhibitors of Hepatitis C virus NS3 protease MERCK SHARP & DOHME CORP. 2007-06-21 — — US disclosed
US-20060247287-A1 Heterocyclic Anti-Viral Compounds Comprising Metabolizable Moieties And Their Uses RIGEL PHARMACEUTICALS, INC. (US) 2006-11-02 — — US disclosed
WO-2005085275-A1 INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE SCHERING CORPORATION (US) 2005-09-15 — — WO disclosed
US-20030153758-A1 1,3,4-Oxadiazole derivatives and process for producing the same ONO PHARMACEUTICAL CO., LTD. 2003-08-14 — — US disclosed
US-6534658-B1 Intermediates for producing pharmaceuticals ONO PHARMACEUTICAL CO., LTD. (JP) 2003-03-18 — — US disclosed
EP-1162199-A1 1,3,4-OXADIAZOLE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2001-12-12 — — EP disclosed
US-5973188-A Acetic acid derivatives HOFFMANN-LA ROCHE INC. (US) 1999-10-26 — — US disclosed
US-5726185-A BINDING OF ADHESIVE PROTEINS TO BLOOD PLATELET AGGREGATION AND CELL TO CELL ADHESION HOFFMANN-LA ROCHE INC. (US) 1998-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428403-B2 N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists SSTR4, SSTR3, SSTR1 CTSK 2395/4885CTSS 1991/4885CA2 2429/4885
US-20070142301-A1 Novel inhibitors of Hepatitis C virus NS3 protease HAVCR2, RNASE1, SERPINB1 CTSK 275/4885CTSS 103/4885CA2 3833/4885
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF KEAP1, NFE2L2, NQO1 CTSK 2667/4885CTSS 3950/4885CA2 4545/4885
US-20060247287-A1 Heterocyclic Anti-Viral Compounds Comprising Metabolizable Moieties And Their Uses HAVCR2, HCCS, AADAC CTSK 1050/4885CTSS 532/4885CA2 4160/4885
US-20030153758-A1 1,3,4-Oxadiazole derivatives and process for producing the same OXA1L, CYP1B1, OXER1 CTSK 3506/4885CTSS 4452/4885CA2 2684/4885
US-20230192659-A1 N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS SSTR4, SSTR3, SSTR1 CTSK 2395/4885CTSS 1991/4885CA2 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.